Literature DB >> 10754464

Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue.

K Kono1, H Naganuma, T Sekikawa, H Amemiya, A Takahashi, H Iizuka, Y Matsumoto.   

Abstract

Serum HER-2/neu (c-erbB-2) levels in patients with gastric cancer were evaluated by an enzyme-linked immunosorbent assay and tissue levels of HER-2/neu in the same cohort were determined by immunohistochemistry. Nine (16%) of 57 gastric carcinomas had an overexpression of HER-2/neu detected immunohistochemically. Of these 9 patients, 6 had elevated serum HER-2/neu levels, while 45 of 48 tissue samples with negative staining exhibited normal serum HER-2/neu levels. These results indicated that overall accuracy, positive predictive value, and negative predictive values of their serum measurements were 89, 67 and 94%, respectively. Serum levels of HER-2/neu were correlated with tissue overexpression of HER-2/neu in patients with gastric cancer. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10754464     DOI： 10.1159/000030120

Source DB:  PubMed          Journal:  Tumour Biol        ISSN： 1010-4283


  8 in total

1.  Is "liquid biopsy" useful for assessing HER2 status in gastric cancer?

Authors:  Hideaki Shimada
Journal:  J Gastroenterol       Date:  2014-05-14       Impact factor: 7.527

2.  Evaluation of serum HER2-ECD levels in patients with gastric cancer.

Authors:  Katsunobu Oyama; Sachio Fushida; Tomoya Tsukada; Jun Kinoshita; Toshifumi Watanabe; Masatoshi Shoji; Shinichi Nakanuma; Koichi Okamoto; Seisho Sakai; Isamu Makino; Keishi Nakamura; Hironori Hayashi; Masafumi Inokuchi; Hisatoshi Nakagawara; Tomoharu Miyashita; Hidehiro Tajima; Hiroyuki Takamura; Itasu Ninomiya; Hirohisa Kitagawa; Takashi Fujimura; Ryousuke Tajiri; Akishi Ooi; Tetsuo Ohta
Journal:  J Gastroenterol       Date:  2014-02-21       Impact factor: 7.527

3.  Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.

Authors:  José Cangiano; Barbara A Centeno; Christopher R Garrett; William Cáceres; Ana de Jesús; Ji-Hyun Lee; Orestes Pavía; Richard Jove; Luis Báez; Daniel M Sullivan; Carlos A Muro-Cacho; Teresita Muñoz-Antonia
Journal:  Dig Dis Sci       Date:  2008-01-26       Impact factor: 3.199

4.  Pilot study of the clinical significance of serum and urinary her-2/neu protein in bladder cancer patients.

Authors:  Taek Sang Kim; Hyun Yul Rhew; Hyun Yong Hwang
Journal:  Korean J Urol       Date:  2011-12-20

Review 5.  Serum HER2 Is a Potential Surrogate for Tissue HER2 Status in Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Kecheng Zhang; Jianxin Cui; Hongqing Xi; Shibo Bian; Liangang Ma; Weisong Shen; Jiyang Li; Ning Wang; Bo Wei; Lin Chen
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

6.  Gastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptor.

Authors:  Henrique O Duarte; Meritxell Balmaña; Stefan Mereiter; Hugo Osório; Joana Gomes; Celso A Reis
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

7.  Expression of HER2/c-erbB-2, EGFR Protein in Gastric Carcinoma and its Clinical Significance.

Authors:  Guoxiong Cheng; Yijun Mei; Xiaoming Pan; Ming Liu; Suping Wu
Journal:  Open Life Sci       Date:  2019-05-13       Impact factor: 0.938

8.  Clinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer.

Authors:  Ozgur Arikan; Asýf Yýldýrým; Banu Ýsbilen; Cengiz Canakci; Gokhan Atýs; Cenk Gurbuz; Bulent Erol; Ferruh Kemal Ýsman; Seyma Ozkanli; Turhan Caskurlu
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.